Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, leading the biotech to terminate the study, abandon the candidate and “review ...

ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing ...

SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /CNW/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") ...

"I've been working international fugitives with the FBI about 26 years… we've arrested a lot of bad guys," says FBI Special Agent Phil Torsney. "This is a once-in-a-lifetime case…and it was certainly ...

If the Every Student Succeeds Act were a schoolchild, it would be a preschooler—not much more than 3 years old, making steady progress, but still stumbling a bit along the way. The first major rewrite ...

Essa Pharma is set to buy floundering Realm Therapeutics. The deal effectively sees Essa trade its shares for Realm’s cash, giving it the financial means to advance its pipeline of cancer drugs. Realm ...

ESSA Pharma (NASDAQ:EPIX) plummeted about 70% premarket on Friday after ending its Phase 2 trial for a prostate cancer treatment. The trial tested masofaniten with enzalutamide versus enzalutamide ...

ESSA Pharma (EPIX) is a Canadian developer of therapies directed specifically at prostate cancer. This is interesting because it is quite rare to see a biotech that's this focused, and that makes it ...

STROUDSBURG, Pa.--(BUSINESS WIRE)--ESSA Bancorp, Inc. (NASDAQ Global Market SM “ESSA”), the parent company of ESSA Bank & Trust, and First Star Bancorp, Inc., (Pinksheets: FSSB), the parent company of ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...